Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Quiz|Articles|November 13, 2026
OncLive Weekly News Quiz (11/13/2026): Did You Miss Crucial TGCT, Breast Cancer, Bladder Cancer, and Lymphoma Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA approved pimicotinib (Pimjetmi) for patients with symptomatic tenosynovial giant cell tumor (TGCT) in whom surgical resection could potentially worsen functional limitations or cause severe morbidity, supported by data from the phase 3 MANEUVER trial (NCT05804045). What type of agent is pimicotinib?
Advertisement
Related to this article
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.
Anktiva plus BCG improved efficacy vs BCG alone in cohort A of QUILT-2.005 in BCG-naive NMIBC.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5